tiprankstipranks
Advertisement
Advertisement

GALT Stock Latest News

Galectin Therapeutics reaches alignment with FDA on belapectin pathway
The FlyGalectin Therapeutics reaches alignment with FDA on belapectin pathway
18d ago
GALT
Galectin Advances Belapectin to Phase 3 After FDA Alignment
PremiumCompany Announcements
Galectin Advances Belapectin to Phase 3 After FDA Alignment
18d ago
8K
GALT
Galectin Therapeutics presents belapectin data at EASL 2026
PremiumThe Fly
Galectin Therapeutics presents belapectin data at EASL 2026
1M ago
GALT
Galectin Therapeutics publishes NAVIGATE Phase 2b trial results
PremiumThe Fly
Galectin Therapeutics publishes NAVIGATE Phase 2b trial results
2M ago
GALT
Galectin Therapeutics files $200M mixed securities shelf
PremiumThe Fly
Galectin Therapeutics files $200M mixed securities shelf
3M ago
GALT
Galectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet
PremiumPre-EarningsGalectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet
4M ago
GALT
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
Premium
Company Announcements
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
4M ago
8K
GALT
Galectin Therapeutics appoints Henry Brem to board of directors
Premium
The Fly
Galectin Therapeutics appoints Henry Brem to board of directors
4M ago
GALT
Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating
PremiumRatings
Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating
4M ago
GALT
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
PremiumCompany Announcements
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
5M ago
GALT
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
PremiumCompany Announcements
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
5M ago
GALT
Galectin Therapeutics Approves Retention Bonuses for Key Executives
PremiumCompany Announcements
Galectin Therapeutics Approves Retention Bonuses for Key Executives
6M ago
8K
GALT
Galectin Therapeutics announces board resignation of Marc Rubin
PremiumCompany AnnouncementsGalectin Therapeutics announces board resignation of Marc Rubin
6M ago
8K
GALT
Galectin Advances Belapectin Program, Secures New Insider Financing
Premium
Company Announcements
Galectin Advances Belapectin Program, Secures New Insider Financing
7M ago
8K
GALT
Galectin Therapeutics provides regulatory update following FDA written response
Premium
The Fly
Galectin Therapeutics provides regulatory update following FDA written response
7M ago
GALT
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
PremiumThe Fly
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
7M ago
GALT
Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
7M ago
8K
GALT
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
PremiumCompany Announcements
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
7M ago
8K
GALT
Galectin Therapeutics Reports Q3 2025 Financials
PremiumCompany Announcements
Galectin Therapeutics Reports Q3 2025 Financials
8M ago
GALT
Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
PremiumRatingsPromising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
8M ago
GALT
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
Premium
The Fly
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
8M ago
GALT
Galectin Therapeutics presents NAVIGATE trial results at AASLD
Premium
The Fly
Galectin Therapeutics presents NAVIGATE trial results at AASLD
8M ago
GALT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >